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ROLE OF TRANSURETHRAL RESECTION OF SUPERFICIAL
BLADDER TUMORS
Jordan Dimanovski and Alek PopoviÊ
Department of Urology, Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY - Thirty percent all primary superficial bladder cancers do not recur at all, and hence
do not need adjuvant treatment. Therefore, the most important isuse is proper selection of patients
who need adjuvant measures. Cystoscopy findings three months after transurethral resection (TUR)
are of paramount importance. If there is no recurrence, patients are in a good prognosis group and
need no further prophylactic measures. Recurrence assessed at that point requires maintance therapy.
Because of the low toxicity and defendable scientific background after any TUR of a tumor that
appears superficial to the clinician, a single administration of a chemotherapeutic agent can be used
within three days of operation in order to prevent tumor cell seeding in the wound bed or elsewhere
in the bladder. After resection of any pT1 (grade III) or Tis tumor, BCG maintenance therapy is
appropriate. The remainder of pTa/pT1(grade I and II) patients should be treated with intravesical
chemotherapy in case of recurrence at three months. For patients who fail to respond to BCG treat-
ment of pT1( grade III) or Tis and who are candidates for radical cystectomy, a new oral agent
bromopirin with interferon inducing properties appears to offer some new hope. Patients with per-
sistent positive high grade malignant citology are candidates for this new treatment.
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Introduction
A majority of bladder neoplasms are either papillary
tumors that involve only the mucosa (Ta) or submucosa
(T1), or flat carcinomas in situ (Tis). The treatment of su-
perficial bladder tumors has three objectives: to eradicate
the existing disease, to inhibit tumor recurrence, and to
prevent progression to muscle invasion or metastasis. Tran-
surethral resection (TUR) is the primary modality for the
removal of  Ta/T1 lesions and focal Tis. TUR does not pre-
vent the development of new tumors, which provides a ra-
tionale for adjuvant therapy. Intravesical therapy after TUR
may be cytotoxic to residual overt or occult carcinomas and
premalignant mucosal lesions.
Natural History
The natural history of superficial bkadder cancer is
largely unpredictable owing to tumor heterogeneity. In
some patients, it is evidenced by rapid progression to deeply
invasive disease but in a majority it is characterized by slow
growth of multiple metachronous tumors that remain con-
fined to the urothelium.
The rates of recurrence after initial TUR vary from 30%
with a solitary papillary tumor to more than 90% in some
cases of multiple tumors. Most lesions recur within 6 to 12
months at the same stage and grade, but between 5% and
30% of all cases exhibit progresion of the disease5.
Multivariate analyses have shown that factors of recur-
rence include a history of superficial tumors, multiple tu-
mors at diagnosis, high tumor grade (grade 3 versus grade
1 and 2), and tumor stage (T1 versus Ta).2,9 Furthermore,
response to therapy is highly significant. Patients whose
disease fails to respond to TUR and intravesical therapy at
3 to 6 months, generally exhibit a pattern of frequent tu-
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mor recurrences10. Thus, the extent and duration of the
disease as well as the early response to therapy help define
the majority of patients who will suffer tumor recurrences
later.
Intravesical therapy for patients at a high risk of tumor
recurrence is a valuable adjunct to TUR. Prevention of su-
perficial tumors is an important goal, as it may spare pa-
tients further urinary symptoms and repeated endoscopic
resections. However, because most tumors recur at the same
low stage and grade, they pose little risk to the patients.
Moreover, the number of tumor recurrences does not cor-
relate with the development of invasive disease. A more ap-
propriate assessment of the efficacy of intravesical therapy
is prevention of disease progression. Stage T1 tumors, es-
pecially those of high grade (grade 3), respond less favor-
ably to TUR and intravesical therapy than Ta or Tis lesions,
and are more likely to progress. Furthermore, patients hav-
ing persistent or recurrent Tis, Ta or T1 cancers despite
therapy are at risk of muscle invasion.
Rationale for Intravesical Therapy
Intravesical therapy is divided into two major catego-
ries: 1) therapeutic, designed to treat established disease;
and 2) prophylactic or adjuvant, designed to prevent recur-
rence and progression. Definitive therapy aims to treat a
disease that cannot be resected surgically. This includes
tumors that are too numerous or too large, inaccessible tu-
mors, some invasive T1 cancers and Tis persisting after a
TUR. Prophylactic therapy is given after a presumed com-
plete TUR as an adjunct to prevent true recurrences due to
incomplete resection or new tumor development resulting
from multiple tumor origins.
Intravesical therapy brings high concentrations of drug
in contact with tumor- bearing mucosa. Tumor implanta-
tion after resection may be inhibited by reducing the num-
ber or viability of free-floating malignant cells. Residual
carcinoma or precursor mucosal lesions may be destroyed,
thus preventing tumor recurrence. Progression of disease
requiring more intense local therapy (cystectomy or sys-
temic chemotherapy) may be delayed. The limited systemic
absorption of intravesical agents minimizes serious toxicty.
Most frequently used intravesical agents are thiotepa, doxo-
rubicin (Adriamycin), mitomycin C, and bacille Calmette-
Guerin (BCG). Individual drug doses and schedules vary
widely. An inductive schedule of  4 to 8 weekly doses is
given. In case of response, this may be followed by monthly
doses for up to 1 year and, in some cases, for 2 years. Aver-
age chemotherapy doses are 30 to 60 mg thiotepa, 40 to 80
doxorubicin, and 20 to 40 mg mitomycin. The BCG prod-
uct is a biological response modifier, and doses vary with
strain: 120 mg (Pasteur), 2-8x108 viable organisms (Tice)
and 60 mg (Connaught). Exceptions to the above doses and
schedules are common.
Prophylactic Intravesical Therapy
In patients treated with TUR alone, the recurrence in-
cidence over 1 year was 43% in patients presenting with
their first Ta/T1 tumor and 70% in pateints with a prior
history of bladder cancer. Overall, intravesical chemo-
therapy produced a small but mesurable effect on the ob-
served recurrence rate, but it was less than that achieved
with BCG. The net reduction in tumor recurrence among
the treated patients relative to patients receiving TUR alone
was 8% for thiotepa, 10% for doxorubicin, 12% for mito-
mycin, and 43 % for BCG.
Definite Intravesical Therapy
The data assembled for multiple studies provide a mini-
mum of 6 months of follow-up and are given as the re-
sponse rates of persistent papillary tumors and carcinoma
in situ combined.5 A complete response (CR) means no
cystoscopic, biopsy or cytologic evidence of disease after
therapy. A partial response (PR) is variously defined as a
reduction in the number of tumors or involved bladder sur-
face area, a 50% reduction in the size of overt lesions, and
in case of Tis, a negative biopsy but positive urine cytolo-
gy study. Failures (NR) are defined as no reduction in tu-
mor number or size, or exhibited progression of disease.
Such data must be interpreted cautiously, because assign-
ing a patient to a definitive response category other than
CR is subjective. In fact, most partial responses are short
lived, and are similar to those in nonresponders.
The rate of complete response to BCG is significantly
greater than that achieved with any of the chemotherapeu-
tic agents, although there appears to be the same advantage
of mitomycin C over doxorubicin or thiotepa. The respon-
ses of papillary tumors versus carcinoma in situ have not
been stratified for the three drugs, whereas BCG seems to
have a greater effect against Tis (73%) than papillary tu-
mors (59%)3,8.
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Recommendations for Therapy
Many patients with primary low-grade (grade 1) pap-
illary tumors derive little benefit from intravesical therapy.
Most are well treated with TUR alone. Patients at highest
risk for tumor recurrence and progression require adjuvant
intravesical therapy after TUR. They include patients with
T1 tumors (especially if multiple), multifocal papillary Ta
cancers (grade 2 or 3), or  Tis and persistently positive uri-
nary cytology emanating from bladder after a TUR, in the
event that all papillary or in situ tumors cannot be resected.
What Agent Should Be Initially Used?
The weight of evidence favors BCG over chemotherapy,
as response rates to BCG appear to be somewhat greater
and generally more durable, especially against carcinoma in
situ4. Approaches other than single-agent instillations that
use combinations of drugs, cycling of agents, and alterna-
tive drugs, are worthy of investigations.
When Should the Disease Be Considered to Have
Failed to Respond to TUR and Intravesical Therapy?
This decision requires endoscopic experience and sound
clinical judgment. A three- month period after the start of
6 to 8 weeks of therapy probably is not long enough to as-
sess the results, but after 6 months one should expect a
complete response to continued use of an active agent (two
courses of treatment). It is unlikely that further intravesi-
cal treatment using the same drug will convert a failure into
complete  remission, and opens the risk of cancer progres-
sion. An occasional recurrent cytologically benign papillary
tumor that is easily fulgurated does not require a radical
change of treatment. However, a positive biopsy for persis-
tent bladder cancer or positive urine citology study strongly
argues for an alternative therapeutic strategy. Furthermore,
there are no controlled studies and only a few circumstan-
tial data to support protracted (maintenance) intravesical
therapy given either therapeutically or prophylactically1.
This is especially true among nonresponders. Inconve-
nience, expense, cumulative toxicity, and above all the risk
of disease progession outweigh any individual long-term
benefit.
For persistent superficial disease (especially Tis), alter-
native intravesical therapy is reasonable but should not be
continued beyond 1 year in nonresponding patients. Per-
sistent T1 disease portends an ominous prognosis, especially
among patients who fail with carcinoma involving prostatic
epithelium. Prostatic involvement, while not strictly a fail-
ure of intravesical therapy, generally demands aggressive
measures. Cystectomy is currently the safest approach.
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Saæetak
ULOGA TRANSURETRALNE RESEKCIJE POVR©INSKIH TUMORA MOKRAÆNOG MJEHURA
J. Dimanovski i A. PopoviÊ
Trideset posto svih primarnih povr¹inskih tumora mokraÊnog mjehura uopÊe ne recidiviraju, stoga ne zahtijevaju dodatno
lijeËenje. Iz tih razloga je vrlo vaæan odabir onih bolesnika koji zaista trebaju dodatne mjere lijeËenja. Od velikog znaËenja je prvi
kontrolni cistoskopski nalaz, tri mjeseca nakon transuretralne resekcije mokraÊnog mjehura zbog tumora. Ne naðu li se znakovi
recidiva osnovne bolesti, prognoza bolesti takvih bolesnika je povoljna te oni ne zahtijevaju dodatno lijeËenje. Ako se naðe recidiv
bolesti, treba razmotriti daljnje modalitete lijeËenja.
KljuËne rijeËi: Neoplazme mokraÊnog mjehura; Neoplazma mokraÊnog mjehura - kirurgija; Neoplazme mokraÊnog mjehura - trendovi
